SOURCE: CDEX, Inc.

September 14, 2007 13:30 ET

CDEX Inc. Files 3rd Quarter Form 10QSB and Form 8K

ValiMed™ 3rd Quarter Revenues and 4th Quarter Sales Contracts Increase

TUCSON, AZ--(Marketwire - September 14, 2007) - CDEX Inc. (OTCBB: CEXI) -- Today, CDEX filed its 3rd Quarter Form 10QSB for FY 2007 reporting, among other things, (1) an increase in revenues over corresponding 2006 revenue figures (e.g., 36% increase in reported revenues for the first 9 months of FY 2007 vs. the first 9 months of FY 2006) and (2) an increase in contracts for the sale or lease of ValiMed™ Units to new and existing hospital clients. In addition, on August 17, 2007, CDEX filed a Form 8K that contains a CDEX information presentation. (Links to the Form 10QSB and Form 8K are located on the CDEX Web Site at www.cdex-inc.com.)

Using Enhanced Photoemission Spectroscopy, a CDEX ValiMed™ Unit quickly validates high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed™ compares a medication's spectroscopic signature to the Unit's medication signature library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation. CDEX is continuing to build the CDEX Medication Signature Library, which currently contains over 88 unique pharmaceutical signatures and is expected to grow to over 150 by the end of 2007.

"We project that during the 4th Quarter of FY 07, CDEX will execute more contracts for the sale or lease of ValiMed™ Units to hospitals than in any quarter to date," stated Malcolm Philips, CEO of CDEX. "As the number of ValiMed™ Units in the field grows, our recurring revenue stream will also continue to grow. The increase in the number of contracts with new and existing clients validates the product expansion efforts that the CDEX Team went through earlier this year."

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

Any statements made in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in the federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its products, the effectiveness, profitability and marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact Information

  • Contact:
    Market News First
    News Agent
    Angela Junell
    214-461-3411
    Ajunell@MN1.com